<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SDU-Denmark_Tour23 skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SDU-Denmark/Tour23</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="BackgroundLayout"><DIV class="top bannerShadow"><DIV class="NavbarContainer"><DIV class="NavbarContainerInner"><DIV class="MenuButton" id="btnWelcome"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark">Welcome</A></DIV><DIV class="MenuButton" id="btnTour"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Interactive wiki-tour</A></DIV><DIV class="MenuButton" id="btnMenu"><A class="MenuButtonLink" href="#" id="btnMenu2">Menu</A><DIV class="menuPopup"><DIV class="menuPopupContent"><DIV class="menuPopupContentInner bannerShadow"><DIV class="menuIntro"><DIV class="warningBox"><P class="menuIntro">
You really should try our <A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">interactive wiki tour</A> instead! 

</P></DIV><P class="menuIntro">
But if you are looking for a specific page - you are in the right place. 
</P><DIV class="menuItems"><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Introduction</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour11">The Team</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour12">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour13">Gallery</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour14">Medal Requirements</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour20"> Antibody Issue</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour21">Antibody Production</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour22">Animal Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour23">The Alternative</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour30">PAST</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour31">Two-Hybrid Screening</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour32">System Design</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour33">Business</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour34">Entrepreneurship</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour40">Process</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour41">Complete Journal</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour42">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour43">SOPs</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour44">Safety</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour50">Results</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour51">Characterization</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour52">Two-Hybrid System</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour53">Submitted Parts</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour54">Interlab Study</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour60">Practices</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour61">Survey</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour62">Education</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour63">Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour64">A Children's Book</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour70">
What is Next?</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour71">Challenges and Limitations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Medical Aspects</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Lab Work</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour73">The End</A></LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="tourBoundingBox"><DIV class="tourBoundingBoxInner bannerShadow"><DIV class="parentTourItem "><A class="tourItemLabel" title="Get a brief overview of the project.">
                Introduction
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="Would you like to meet our team?">
                       The Team
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="To express our thankfulness.">
                        Attributions
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Gallery
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medal Requirements
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               Antibody issue
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Antibody production
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Animal Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        The Alternative
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                PAST            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Two-Hybrid Screening
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        System Design
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Business
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Entrepreneurship
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                Process
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Complete Journal
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Collaborations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       SOPs
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Safety
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">       Results
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Characterization
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      Two-Hybrid System
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Submitted Parts
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Interlab Study
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
Practices
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Survey
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Education
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title=""> A Children’s Book
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               What is Next
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Challenges and Limitations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medical Aspects
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Lab Work
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      The End
                    </A></DIV></DIV></DIV></DIV></DIV><DIV class="MainLayout"><DIV class="content"><DIV><P><I> &quot;Think different&quot; - <B> Apple Inc.</B></I></P><H1 align="center"> The Alternative </H1><P><SPAN class="intro">Antibodies have</SPAN> provided many useful applications throughout the years, both in therapeutics and in research. However, the expensiveness and time-consuming part of antibody production entails that research and development of alternatives is needed. We need to think differently.
</P><P><SPAN class="intro"> Peptide aptamers make up one alternative. </SPAN> These combinatorial recognition proteins have been known for more than 15  <SPAN class="sourceReference">years</SPAN><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
    Colas P. The eleven-year switch of peptide aptamers. Journal of biology. 2008;7(1):2.

Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 1996;380(6574):548-50.
</SPAN>  
and they provide high specificity and strong binding affinity (see table 1). 

<B>Peptide aptamers</B> consist of a variable peptide sequence inserted into a scaffold protein. It is through this variable loop that they bind their target. Various scaffolds have been used as carriers and conformational stabilizers of peptide aptamers. Of the most frequently used is the bacterial and human thioredoxin <SPAN class="sourceReference">(hTrx)</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
    Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Molecular cancer research : MCR. 2008;6(2):267-81. 
</SPAN>  In our project we construct a system for screening peptide aptamers presented in latter. See figure 1 for a predicted structure. 
</P><P><TABLE id="Table1" class="wikitable" style="width:90%;margin-left:50px;"><CAPTION><B>Table 1:</B> Binding affinites for monoclonal antibodies and peptide aptamers.
</CAPTION><TBODY><TR><TD><B>Peptide aptamers</B></TD><TD><B>Monoclonal antibodies</B></TD></TR><TR><TD><B>Affinity (K<SUB>D</SUB>)</B></TD><TD>10 to 100 nM</TD><TD>10<SUP>-3</SUP> to 100 nM</TD></TR></TBODY></TABLE></P><P><SPAN class="intro"> In order to maintain the combinatorial ability </SPAN> and diverse specificity of the antibodies, the peptide aptamers have a random peptide loop. These are typical from 10 to 20 amino acids long. To construct these combinatorial peptide libraries, twenty (or ten) repeats of the codon

<SPAN class="tooltipLink">3'-NNK-5'</SPAN><SPAN class="tooltip"><SPAN class="tooltipHeader">3'-NNK-5'</SPAN> N represents any of the four nucleotides; adenine (A), thymine (T), cytosine (C), and guanine (G). K represents either G or C. This restriction will limit the chance of a stop-codon occuring in the sequence. In a 60 nucleotide sequence, this means that 4<SUP>40</SUP>x2<SUP>20</SUP> = 1,27x10<SUP>30</SUP> different sequences could be generated.
</SPAN>
is inserted into the gene encoding the scaffold protein. If the variable loop is 20 amino acids long, one will get 20<SUP>20</SUP>=1,05×10<SUP>26</SUP> different peptide combinations. This should give enough diversification to resemble the diversity of antibodies.  
</P><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px;height:365px;"><DIV class="thumbcaption">Figure 1: A predicted Peptide Aptamer structure using Phyre<SUP>2</SUP>.</DIV></DIV></DIV><P><SPAN class="intro"> Why did we choose </SPAN> the hTrx-based peptide aptamer as our alternative to the antibody? In contrary to antibodies, peptide aptamers are small monomeric proteins that have been proven to be efficiently expressed and produced in bacteria such as <I>Escherichia coli</I> - especially when presented in a human thioredoxin scaf<SPAN class="sourceReference">fold</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
    Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Molecular cancer research : MCR. 2008;6(2):267-81. 
</SPAN> Because of their high specificity and strong binding affinity, it has been proposed and verified that they can replace antibodies in many methods involving protein detec<SPAN class="sourceReference">tion</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
    Evans D, Johnson S, Laurenson S, Davies AG, Ko Ferrigno P, Wälti C. Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays. Journal of biology. 2008;7(1):3.
</SPAN> Specific peptide aptamers with anticancer and antiviral activity have already been identi<SPAN class="sourceReference">fied</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
    Li J, Tan S, Chen X, Zhang CY, Zhang Y. Peptide aptamers with biological and therapeutic applications. Current medicinal chemistry. 2011;18(27):4215-22.
</SPAN> Even though they are well described and characterized, peptide aptamers are not used to the same extent as antibodies. 
</P><P><SPAN class="intro"> in therapeutic applications </SPAN>, the peptide aptamer must not be immunogenic in humans. By choosing a protein of human origin as the scaffold protein, like the human thioredoxin, we expect it to be less immunogenic than other potential scaffolds. With an estimated half-life of 100 <SPAN class="sourceReference">hours</SPAN>,
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
   Swiss Institute of Bioinformatics. 2015. Available from: http://web.expasy.org/cgi-bin/protparam/protparam1?P10599%402-105.
</SPAN> the human thioredoxin provides a stable scaffold and helps prevent the peptide aptamer for premature degradation. This is of course the half-life of the non-recombinant hTrx. The half-life for the recombinant hTrx is probably influenced by the insertion of the randomly generated peptide sequence.
</P><P><SPAN class="intro"> Peptide aptamers are by far not the only </SPAN> antibody mimetics known. Other affinity proteins have been studied throughout the years - and few even commerciali<SPAN class="sourceReference">zed</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
   Key Benefits: Affimers have some simple but essential advantages over antibodies: Avacta Life Sciences;  [updated 19-08-2015]. Available from: https://www.avactalifesciences.com/key-benefits.
</SPAN> However the market is very small. We believe that the hTrx-based peptide aptamer in combination with the <A href="https://2015.igem.org/Team:SDU-Denmark/Tour30">bacterial two-hybrid screening</A> method provides an easy and fast alternative to antibody production. 
</P></DIV></DIV><DIV class="footer "><DIV class="footerContainer"><A class="footerBtn footerShadow" id="btnFastForward"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnNextChapter"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnDigDeeper"><P class="footerBtnPre">Dig deeper
</P></A><A class="footerBtn footerShadow" id="btnTheEnd" href="http://www.igem.org" target="_blank"><P class="footerBtnPre">End of tour
</P><P class="footerBtnHeader" style="text-transform: none !important;">Want more? Go to iGEM.org!</P><P class="footerBtnText">
If you want to learn more about Synthetic Biology you should visit iGEM's homepage, which contains loads on the subject. You can even visit other teams' wikis and take a look at what they accomplished. Or maybe join a team yourself?</P></A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>